Generic Rinvoq Availability

Last updated on Nov 6, 2024.

See also: Generic Rinvoq LQ

Rinvoq is a brand name of upadacitinib, approved by the FDA in the following formulation(s):

RINVOQ (upadacitinib - tablet, extended release;oral)

• Manufacturer: ABBVIE
  Approval date: August 16, 2019
  Strength(s): 15MG ^[RLD]
• Manufacturer: ABBVIE
  Approval date: January 14, 2022
  Strength(s): 30MG ^[RLD]
• Manufacturer: ABBVIE
  Approval date: March 16, 2022
  Strength(s): 45MG ^[RLD]

Has a generic version of Rinvoq been approved?

No. There is currently no therapeutically equivalent version of Rinvoq available in the United States.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Rinvoq. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: Generic Drug FAQ.

Related patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-α]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
  Patent 10,202,393
  Issued: February 12, 2019
  Inventor(s): Jayanth Jayanthy & Marroum Patrick J. & Mayer Peter T. & Mohamed Mohamed-Eslam F. & Othman Ahmed A. & Klünder Ben
  Assignee(s): AbbVie Inc.
  

  The present disclosure relates to processes for preparing (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide, solid state forms thereof, and corresponding pharmaceutical compositions, methods of treatment (including treatment of rheumatoid arthritis), kits, methods of synthesis, and products-by-process.

  Patent expiration dates:

  • October 17, 2036
    
    ✓ 
    Drug product
• Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-#a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-#carboxamide and solid state forms thereof
  Patent 10,344,036
  Issued: July 9, 2019
  Inventor(s): Jayanth Jayanthy & Marroum Patrick J. & Mayer Peter T. & Mohamed Mohamed-Eslam F. & Othman Ahmed A. & Klünder Ben & Allian Ayman
  Assignee(s): AbbVie Inc.
  

  The present disclosure relates to processes for preparing (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide, solid state forms thereof, and corresponding pharmaceutical compositions, methods of treatment (including treatment of rheumatoid arthritis), kits, methods of synthesis, and products-by-process.

  Patent expiration dates:

  • October 17, 2036
    
    ✓ 
    Drug product
• Processes for the preparation of (3S,4R)-3,ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
  Patent 10,519,164
  Issued: December 31, 2019
  Inventor(s): Allian Ayman & Jayanth Jayanthy & Klünder Ben & Mohamed Mohamed-Eslam F. & Othman Ahmed A. & Marroum Patrick J. & Mayer Peter T.
  Assignee(s): AbbVie Inc.
  

  The present disclosure relates to processes for preparing (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide, solid state forms thereof, and corresponding pharmaceutical compositions, methods of treatment (including treatment of rheumatoid arthritis), kits, methods of synthesis, and products-by-process.

  Patent expiration dates:

  • October 17, 2036
    
    ✓ 
    Drug product
• Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-A]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
  Patent 10,550,126
  Issued: February 4, 2020
  Inventor(s): Pangan Aileen L. & Teixeira Henrique D. & Mohamed Mohamed-Eslam F. & Othman Ahmed A. & Klünder Ben
  Assignee(s): AbbVie Inc.
  

  The present disclosure relates to processes for preparing (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-α]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide, solid state forms thereof, and corresponding pharmaceutical compositions, methods of treatment (including treatment of rheumatoid arthritis and atopic dermatitis), kits, methods of synthesis, and products-by-process.

  Patent expiration dates:

  • October 17, 2036
    
    ✓ 
    Patent use: TREATMENT OF ADULTS AND PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER WITH REFRACTORY, MODERATE TO SEVERE ATOPIC DERMATITIS WHOSE DISEASE IS NOT ADEQUATELY CONTROLLED WITH OTHER SYSTEMIC DRUG PRODUCTS, OR WHEN USE OF THOSE THERAPIES ARE INADVISABLE
• Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carb oxamide and solid state forms thereof
  Patent 10,597,400
  Issued: March 24, 2020
  Inventor(s): Othman Ahmed A. & Mohamed Mohamed-Eslam F. & Klünder Ben & Pangan Aileen L.
  Assignee(s): AbbVie Inc.
  

  The present disclosure relates to processes for preparing (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide, solid state forms thereof, and corresponding pharmaceutical compositions, methods of treatment (including treatment of rheumatoid arthritis), kits, methods of synthesis, and products-by-process.

  Patent expiration dates:

  • October 17, 2036
    
    ✓ 
    Patent use: TREATMENT OF ADULTS WITH MODERATELY TO SEVERELY ACTIVE RHEUMATOID ARTHRITIS WHO HAVE HAD AN INADEQUATE RESPONSE OR INTOLERANCE TO ONE OR MORE TNF BLOCKERS
• Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
  Patent 10,730,883
  Issued: August 4, 2020
  Inventor(s): Allian Ayman & Jayanth Jayanthy & Klünder Ben & Mohamed Mohamed-Eslam F. & Othman Ahmed A. & Marroum Patrick J. & Mayer Peter T.
  Assignee(s): AbbVie Inc.
  

  The present disclosure relates to processes for preparing (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide, solid state forms thereof, and corresponding pharmaceutical compositions, methods of treatment (including treatment of rheumatoid arthritis), kits, methods of synthesis, and products-by-process.

  Patent expiration dates:

  • October 17, 2036
    
    ✓ 
    Drug product
• Patent 10,981,923
  

  Patent expiration dates:

  • October 17, 2036
    
    ✓ 
    Drug substance
• Patent 10,981,924
  

  Patent expiration dates:

  • October 17, 2036
    
    ✓ 
    Drug product
• Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carb oxamide and solid state forms thereof
  Patent 10,995,095
  Issued: May 4, 2021
  Inventor(s): Pangan Aileen L. & Teixeira Henrique D. & Mohamed Mohamed-Eslam F. & Othman Ahmed A. & Klünder Ben
  Assignee(s): AbbVie Inc.
  

  The present disclosure relates to processes for preparing (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide, solid state forms thereof, and corresponding pharmaceutical compositions, methods of treatment (including treatment of rheumatoid arthritis and atopic dermatitis), kits, methods of synthesis, and products-by-process.

  Patent expiration dates:

  • October 17, 2036
    
    ✓ 
    Patent use: TREATMENT OF ADULTS AND PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER WITH REFRACTORY, MODERATE TO SEVERE ATOPIC DERMATITIS WHOSE DISEASE IS NOT ADEQUATELY CONTROLLED WITH OTHER SYSTEMIC DRUG PRODUCTS, OR WHEN USE OF THOSE THERAPIES ARE INADVISABLE
• Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
  Patent 11,186,584
  Issued: November 30, 2021
  Inventor(s): Allian Ayman & Jayanth Jayanthy & Mohamed Mohamed-Eslam F. & Mulhern Mathew & Nordstrom Fredrik Lars & Othman Ahmed A. & Rozema Michael J. & Bhagavatula Lakshmi & Marroum Patrick J. & Mayer Peter T. & Sheikh Ahmad Y. & Borchardt Thomas B. & Klünder Ben
  Assignee(s): AbbVie Inc.
  

  The present disclosure relates to processes for preparing (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide, solid state forms thereof, and corresponding pharmaceutical compositions, methods of treatment (including treatment of rheumatoid arthritis), kits, methods of synthesis, and products-by-process.

  Patent expiration dates:

  • October 17, 2036
    
    ✓ 
    Drug substance
• Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
  Patent 11,198,697
  Issued: December 14, 2021
  Inventor(s): Allian Ayman & Jayanth Jayanthy & Mohamed Mohamed-Eslam F. & Mulhern Mathew & Nordstrom Fredrik Lars & Othman Ahmed A. & Rozema Michael J. & Bhagavatula Lakshmi & Marroum Patrick J. & Mayer Peter T. & Sheikh Ahmad Y. & Borchardt Thomas B. & Klünder Ben
  Assignee(s): AbbVie Inc.
  

  The present disclosure relates to processes for preparing (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide, solid state forms thereof, and corresponding pharmaceutical compositions, methods of treatment (including treatment of rheumatoid arthritis), kits, methods of synthesis, and products-by-process.

  Patent expiration dates:

  • October 17, 2036
    
    ✓ 
    Drug product
• Patent 11,365,198
  

  Patent expiration dates:

  • October 17, 2036
    
    ✓ 
    Patent use: TREATMENT OF PEDIATRIC PATIENTS 2 YEARS OF AGE AND OLDER WITH ACTIVE PSORIATIC ARTHRITIS WHO HAVE HAD AN INADEQUATE RESPONSE OR INTOLERANCE TO ONE OR MORE TNF BLOCKERS
  • October 17, 2036
    
    ✓ 
    Patent use: TREATMENT OF ADULTS WITH ACTIVE PSORIATIC ARTHRITIS WHO HAVE HAD AN INADEQUATE RESPONSE OR INTOLERANCE TO ONE OR MORE TNF BLOCKERS
• Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
  Patent 11,512,092
  Issued: November 29, 2022
  Inventor(s): Allian Ayman & Jayanth Jayanthy & Mohamed Mohamed-Eslam F. & Mulhern Mathew & Nordstrom Fredrik Lars & Othman Ahmed A. & Rozema Michael J. & Bhagavatula Lakshmi & Marroum Patrick J. & Mayer Peter T. & Sheikh Ahmad Y. & Borchardt Thomas B. & Klünder Ben
  Assignee(s): AbbVie Inc.
  

  The present disclosure relates to processes for preparing (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide, solid state forms thereof, and corresponding pharmaceutical compositions, methods of treatment (including treatment of rheumatoid arthritis and various spondyloarthritic conditions, including types of axial spondyloarthritis (axSpA)), kits, methods of synthesis, and products-by-process. In various aspects, provided are methods for treating active non-radiographic axSpA (nr-axSpA) and methods for treating active ankylosing spondylitis (AS).

  Patent expiration dates:

  • October 17, 2036
    
    ✓ 
    Patent use: TREATMENT OF PEDIATRIC PATIENTS 2 YEARS OF AGE AND OLDER WITH ACTIVE PSORIATIC ARTHRITIS WHO HAVE HAD AN INADEQUATE RESPONSE OR INTOLERANCE TO ONE OR MORE TNF BLOCKERS
  • October 17, 2036
    
    ✓ 
    Patent use: TREATMENT OF ADULTS WITH ACTIVE PSORIATIC ARTHRITIS WHO HAVE HAD AN INADEQUATE RESPONSE OR INTOLERANCE TO ONE OR MORE TNF BLOCKERS
  • October 17, 2036
    
    ✓ 
    Patent use: TREATMENT OF ADULTS WITH ACTIVE NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS WITH OBJECTIVE SIGNS OF INFLAMMATION WHO HAVE HAD AN INADEQUATE RESPONSE OR INTOLERANCE TO ONE OR MORE TNF BLOCKERS
  • October 17, 2036
    
    ✓ 
    Patent use: TREATMENT OF ADULTS WITH ACTIVE ANKYLOSING SPONDYLITIS WHO HAVE HAD AN INADEQUATE RESPONSE OR INTOLERANCE TO ONE OR MORE TNF BLOCKERS
• Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
  Patent 11,524,964
  Issued: December 13, 2022
  Inventor(s): Mohamed Mohamed-Eslam F. & Othman Ahmed A. & Klünder Ben & Pangan Aileen L. & Song In-Ho
  Assignee(s): Abbvie Inc.
  

  The present disclosure relates to processes for preparing (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide, solid state forms thereof, and corresponding pharmaceutical compositions, methods of treatment (including treatment of rheumatoid arthritis and various spondyloarthritic conditions, including types of axial spondyloarthritis (axSpA)), kits, methods of synthesis, and products-by-process. In various aspects, provided are methods for treating active non-radiographic axSpA (nr-axSpA) and methods for treating active ankylosing spondylitis (AS).

  Patent expiration dates:

  • October 17, 2036
    
    ✓ 
    Patent use: TREATMENT OF ADULTS WITH ACTIVE ANKYLOSING SPONDYLITIS WHO HAVE HAD AN INADEQUATE RESPONSE OR INTOLERANCE TO ONE OR MORE TNF BLOCKERS
• Patent 11,535,624
  

  Patent expiration dates:

  • October 17, 2036
    
    ✓ 
    Patent use: TREATMENT OF ADULTS WITH MODERATELY TO SEVERELY ACTIVE RHEUMATOID ARTHRITIS WHO HAVE HAD AN INADEQUATE RESPONSE OR INTOLERANCE TO ONE OR MORE TNF BLOCKERS
• Patent 11,535,625
  

  Patent expiration dates:

  • October 17, 2036
    
    ✓ 
    Patent use: TREATMENT OF ADULTS AND PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER WITH REFRACTORY, MODERATE TO SEVERE ATOPIC DERMATITIS WHOSE DISEASE IS NOT ADEQUATELY CONTROLLED WITH OTHER SYSTEMIC DRUG PRODUCTS, OR WHEN USE OF THOSE THERAPIES ARE INADVISABLE
• Patent 11,535,626
  

  Patent expiration dates:

  • October 17, 2036
    
    ✓ 
    Patent use: TREATMENT OF ADULTS AND PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER WITH REFRACTORY, MODERATE TO SEVERE ATOPIC DERMATITIS WHOSE DISEASE IS NOT ADEQUATELY CONTROLLED WITH OTHER SYSTEMIC DRUG PRODUCTS, OR WHEN USE OF THOSE THERAPIES ARE INADVISABLE
• Patent 11,564,922
  

  Patent expiration dates:

  • March 9, 2038
    
    ✓ 
    Patent use: TREATMENT OF ADULTS WITH MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE WHO HAVE HAD AN INADEQUATE RESPONSE OR INTOLERANCE TO ONE OR MORE TNF BLOCKERS
• Patent 11,607,411
  

  Patent expiration dates:

  • March 9, 2038
    
    ✓ 
    Patent use: TREATMENT OF ADULTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS WHO HAVE HAD AN INADEQUATE RESPONSE OR INTOLERANCE TO ONE OR MORE TNF BLOCKERS
• Patent 11,661,425
  

  Patent expiration dates:

  • October 17, 2036
    
    ✓ 
    Drug substance
    ✓ 
    Drug product
• Patent 11,680,069
  

  Patent expiration dates:

  • October 17, 2036
    
    ✓ 
    Drug substance
    ✓ 
    Drug product
• Patent 11,718,627
  

  Patent expiration dates:

  • October 17, 2036
    
    ✓ 
    Drug substance
    ✓ 
    Drug product
• Patent 11,767,326
  

  Patent expiration dates:

  • October 17, 2036
    
    ✓ 
    Patent use: TREATMENT OF ADULTS AND PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER WITH REFRACTORY, MODERATE TO SEVERE ATOPIC DERMATITIS WHOSE DISEASE IS NOT ADEQUATELY CONTROLLED WITH OTHER SYSTEMIC DRUG PRODUCTS, OR WHEN USE OF THOSE THERAPIES ARE INADVISABLE
• Patent 11,773,105
  

  Patent expiration dates:

  • October 17, 2036
    
    ✓ 
    Drug substance
    ✓ 
    Drug product
• Patent 11,773,106
  

  Patent expiration dates:

  • October 17, 2036
    
    ✓ 
    Patent use: TREATMENT OF PEDIATRIC PATIENTS 2 YEARS OF AGE AND OLDER WITH ACTIVE PSORIATIC ARTHRITIS WHO HAVE HAD AN INADEQUATE RESPONSE OR INTOLERANCE TO ONE OR MORE TNF BLOCKERS
  • October 17, 2036
    
    ✓ 
    Patent use: TREATMENT OF ADULTS WITH ACTIVE PSORIATIC ARTHRITIS WHO HAVE HAD AN INADEQUATE RESPONSE OR INTOLERANCE TO ONE OR MORE TNF BLOCKERS
  • October 17, 2036
    
    ✓ 
    Patent use: TREATMENT OF ADULTS WITH ACTIVE NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS WITH OBJECTIVE SIGNS OF INFLAMMATION WHO HAVE HAD AN INADEQUATE RESPONSE OR INTOLERANCE TO ONE OR MORE TNF BLOCKERS
  • October 17, 2036
    
    ✓ 
    Patent use: TREATMENT OF ADULTS WITH ACTIVE ANKYLOSING SPONDYLITIS WHO HAVE HAD AN INADEQUATE RESPONSE OR INTOLERANCE TO ONE OR MORE TNF BLOCKERS
• Patent 11,780,847
  

  Patent expiration dates:

  • October 17, 2036
    
    ✓ 
    Drug product
• Patent 11,780,848
  

  Patent expiration dates:

  • October 17, 2036
    
    ✓ 
    Patent use: TREATMENT OF ADULTS WITH ACTIVE ANKYLOSING SPONDYLITIS WHO HAVE HAD AN INADEQUATE RESPONSE OR INTOLERANCE TO ONE OR MORE TNF BLOCKERS
• Patent 11,787,815
  

  Patent expiration dates:

  • October 17, 2036
    
    ✓ 
    Drug product
• Patent 11,795,175
  

  Patent expiration dates:

  • October 17, 2036
    
    ✓ 
    Patent use: TREATMENT OF ADULTS WITH MODERATELY TO SEVERELY ACTIVE RHEUMATOID ARTHRITIS WHO HAVE HAD AN INADEQUATE RESPONSE OR INTOLERANCE TO ONE OR MORE TNF BLOCKERS
• Patent 11,976,077
  

  Patent expiration dates:

  • October 17, 2036
    
    ✓ 
    Patent use: TREATMENT OF ADULTS AND PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER WITH REFRACTORY, MODERATE TO SEVERE ATOPIC DERMATITIS WHOSE DISEASE IS NOT ADEQUATELY CONTROLLED WITH OTHER SYSTEMIC DRUG PRODUCTS, OR WHEN USE OF THOSE THERAPIES ARE INADVISABLE
• Patent 11,993,605
  

  Patent expiration dates:

  • October 17, 2036
    
    ✓ 
    Patent use: TREATMENT OF ADULTS WITH ACTIVE PSORIATIC ARTHRITIS WHO HAVE HAD AN INADEQUATE RESPONSE OR INTOLERANCE TO ONE OR MORE TNF BLOCKERS
  • October 17, 2036
    
    ✓ 
    Patent use: TREATMENT OF PEDIATRIC PATIENTS 2 YEARS OF AGE AND OLDER WITH ACTIVE PSORIATIC ARTHRITIS WHO HAVE HAD AN INADEQUATE RESPONSE OR INTOLERANCE TO ONE OR MORE TNF BLOCKERS
• Patent 11,993,606
  

  Patent expiration dates:

  • October 17, 2036
    
    ✓ 
    Patent use: TREATMENT OF ADULTS WITH ACTIVE NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS WITH OBJECTIVE SIGNS OF INFLAMMATION WHO HAVE HAD AN INADEQUATE RESPONSE OR INTOLERANCE TO ONE OR MORE TNF BLOCKERS
• Patent 12,077,545
  

  Patent expiration dates:

  • October 17, 2036
    
    ✓ 
    Drug product
• Patent 12,091,415
  

  Patent expiration dates:

  • October 17, 2036
    
    ✓ 
    Drug product
• Patent 12,103,933
  

  Patent expiration dates:

  • October 17, 2036
    
    ✓ 
    Drug product
• Tricyclic compounds
  Patent 8,962,629
  Issued: February 24, 2015
  Inventor(s): Wishart Neil & Argiriadi Maria A. & Calderwood David J. & Ericsson Anna M. & Fiamengo Bryan A. & Frank Kristine E. & Friedman Michael M. & George Dawn M. & Goedken Eric R. & Josephsohn Nathan S. & Li Biqin C. & Stewart Kent D. & Wallace Grier A. & Wang Lu & Woller Kevin R.
  Assignee(s): AbbVie Inc.
  

  The invention provides a compound of Formula (I)

  Patent expiration dates:

  • January 15, 2031
    
    ✓ 
    Patent use: TREATMENT OF ADULTS WITH ACTIVE ANKYLOSING SPONDYLITIS WHO HAVE HAD AN INADEQUATE RESPONSE OR INTOLERANCE TO ONE OR MORE TNF BLOCKERS
    ✓ 
    Drug substance
  • January 15, 2031
    
    ✓ 
    Patent use: TREATMENT OF ADULTS WITH MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE WHO HAVE HAD AN INADEQUATE RESPONSE OR INTOLERANCE TO ONE OR MORE TNF BLOCKERS
    ✓ 
    Drug substance
  • January 15, 2031
    
    ✓ 
    Patent use: TREATMENT OF PEDIATRIC PATIENTS 2 YEARS OF AGE AND OLDER WITH ACTIVE PSORIATIC ARTHRITIS WHO HAVE HAD AN INADEQUATE RESPONSE OR INTOLERANCE TO ONE OR MORE TNF BLOCKERS
    ✓ 
    Drug substance
  • January 15, 2031
    
    ✓ 
    Patent use: TREATMENT OF PATIENTS 2 YEARS OF AGE AND OLDER WITH ACTIVE POLYARTICULAR JUVENILE IDIOPATHIC ARTHRITIS WHO HAVE HAD AN INADEQUATE RESPONSE OR INTOLERANCE TO ONE OR MORE TNF BLOCKERS
    ✓ 
    Drug substance
  • January 15, 2031
    
    ✓ 
    Patent use: TREATMENT OF ADULTS WITH ACTIVE PSORIATIC ARTHRITIS WHO HAVE HAD AN INADEQUATE RESPONSE OR INTOLERANCE TO ONE OR MORE TNF BLOCKERS
    ✓ 
    Drug substance
  • January 15, 2031
    
    ✓ 
    Patent use: TREATMENT OF ADULTS WITH MODERATELY TO SEVERELY ACTIVE RHEUMATOID ARTHRITIS WHO HAVE HAD AN INADEQUATE RESPONSE OR INTOLERANCE TO ONE OR MORE TNF BLOCKERS
    ✓ 
    Drug substance
  • January 15, 2031
    
    ✓ 
    Patent use: TREATMENT OF ADULTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS WHO HAVE HAD AN INADEQUATE RESPONSE OR INTOLERANCE TO ONE OR MORE TNF BLOCKERS
    ✓ 
    Drug substance
• Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-alpha]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
  Patent 9,951,080
  Issued: April 24, 2018
  Inventor(s): Allian Ayman
  Assignee(s): AbbVie Inc.
  

  The present disclosure relates to processes for preparing (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide, solid state forms thereof, and corresponding pharmaceutical compositions, methods of treatment (including treatment of rheumatoid arthritis), kits, methods of synthesis, and products-by-process.

  Patent expiration dates:

  • October 17, 2036
    
    ✓ 
    Drug substance
    ✓ 
    Drug product
• Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-alpla]pyrrolo[2,3-e]-pyrazin-8-YL)-N-(2,2,2-Trifluoroethyl)pyrrol and solid state forms thereof
  Patent 9,963,459
  Issued: May 8, 2018
  Inventor(s): Jayanth Jayanthy & Marroum Patrick J. & Mayer Peter T. & Mohamed Mohamed-Eslam F. & Othman Ahmed A.
  Assignee(s): AbbVie Inc.
  

  The present disclosure relates to processes for preparing (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide, solid state forms thereof, and corresponding pharmaceutical compositions, methods of treatment (including treatment of rheumatoid arthritis), kits, methods of synthesis, and products-by-process.

  Patent expiration dates:

  • October 17, 2036
    
    ✓ 
    Drug product
• Tricyclic compounds
  Patent RE47221
  Issued: February 5, 2019
  Inventor(s): Wishart Neil & Frank Kristine E. & Friedman Michael & George Dawn M. & Stewart Kent D. & Wallace Grier A.
  Assignee(s): AbbVie Inc.
  

  The invention provides compounds of Formula (I) and Formula (II)

  Patent expiration dates:

  • August 16, 2033
    
    ✓ 
    Drug substance

Related exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

• Exclusivity expiration dates:

  • August 16, 2024 - NEW CHEMICAL ENTITY
  • December 14, 2024 - TREATMENT OF ADULTS WITH ACTIVE PSORIATIC ARTHRITIS WHO HAVE HAD AN INADEQUATE RESPONSE OR INTOLERANCE TO ONE OR MORE TNF BLOCKERS
  • January 14, 2025 - TREATMENT OF ADULTS AND PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER WITH REFRACTORY, MODERATE-TO-SEVERE ATOPIC DERMATITIS WHOSE DISEASE IS NOT ADEQUATELY CONTROLLED WITH OTHER SYSTEMIC DRUG PRODUCTS, INCLUDING BIOLOGICS, OR WHEN USE OF THOSE THERAPIES AR
  • March 16, 2025 - TREATMENT OF ADULT PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS WHO HAVE HAD AN INADEQUATE RESPONSE OR INTOLERANCE TO ONE OR MORE TNF BLOCKERS
  • April 29, 2025 - TREATMENT OF ADULTS WITH ACTIVE ANKYLOSING SPONDYLITIS WHO HAVE HAD AN INADEQUATE RESPONSE OR INTOLERANCE TO ONE OR MORE TNF BLOCKERS
  • May 18, 2026 - TREATMENT OF ADULT PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE WHO HAVE HAD AN INADEQUATE RESPONSE OR INTOLERANCE TO ONE OR MORE TNF BLOCKERS
  • April 26, 2027 - NEW PATIENT POPULATION
  • April 26, 2027 - TREATMENT OF PATIENTS 2 YEARS OF AGE AND OLDER WITH ACTIVE POLYARTICULAR JUVENILE IDIOPATHIC ARTHRITIS (PJIA) WHO HAVE HAD AN INADEQUATE RESPONSE OR INTOLERANCE TO ONE OF MORE TUMOR NECROSIS FACTOR (TNF) BLOCKERS
  • April 26, 2031 - TREATMENT OF PEDIATRIC PATIENTS 2 YEARS OF AGE AND OLDER WITH ACTIVE POLYARTICULAR JUVENILE IDIOPATHIC ARTHRITIS WHO HAVE HAD AN INADEQUATE RESPONSE OR INTOLERANCE TO ONE OR MORE TUMOR NECROSIS FACTOR (TNF) BLOCKERS, AND FOR THE TREATMENT OF PEDIATRIC PAT

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer